检索结果 - Jay Tibbitts

  • Showing 1 - 10 results of 10
Refine Results
  1. 1
    Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and development

    Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and development 由 Jay Tibbitts, David Canter, Ryan Graff, Alison Smith, Leslie A. Khawli

    出版 2015
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  2. 2
    High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)–mediated inhibition of platelet production

    High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)–mediated inhibition of platelet production 由 Jonathan N. Thon, Matthew T. Devine, Antonija Jurak Begonja, Jay Tibbitts, Joseph E. Italiano

    出版 2012
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  3. 3
    A Mechanistic Pharmacokinetic Model Elucidating the Disposition of Trastuzumab Emtansine (T-DM1), an Antibody–Drug Conjugate (ADC) for Treatment of Metastatic Breast Cancer

    A Mechanistic Pharmacokinetic Model Elucidating the Disposition of Trastuzumab Emtansine (T-DM1), an Antibody–Drug Conjugate (ADC) for Treatment of Metastatic Breast Cancer 由 Brendan C. Bender, Douglas D. Leipold, Keyang Xu, Ben‐Quan Shen, Jay Tibbitts, Lena E. Friberg

    出版 2014
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  4. 4
    Semi-mechanistic Population Pharmacokinetic Model of Multivalent Trastuzumab Emtansine in Patients with Metastatic Breast Cancer

    Semi-mechanistic Population Pharmacokinetic Model of Multivalent Trastuzumab Emtansine in Patients with Metastatic Breast Cancer 由 Vaishali L. Chudasama, Franziska Schaedeli Stark, John M. Harrold, Jay Tibbitts, Sandhya Girish, Manish Gupta, Norbert Frey, Donald E. Mager

    出版 2012
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  5. 5
    Preclinical safety profile of trastuzumab emtansine (T-DM1): Mechanism of action of its cytotoxic component retained with improved tolerability

    Preclinical safety profile of trastuzumab emtansine (T-DM1): Mechanism of action of its cytotoxic component retained with improved tolerability 由 Kirsten Achilles Poon, Kelly M. Flagella, Joseph C. Beyer, Jay Tibbitts, Surinder Kaur, Ola M. Saad, Joo-Hee Yi, Sandhya Girish, Noël Dybdal, Theresa Reynolds

    出版 2013
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  6. 6
    Antitumor Activity of Targeted and Cytotoxic Agents in Murine Subcutaneous Tumor Models Correlates with Clinical Response

    Antitumor Activity of Targeted and Cytotoxic Agents in Murine Subcutaneous Tumor Models Correlates with Clinical Response 由 Harvey Wong, Edna F. Choo, Bruno Alicke, Xiao Ding, Hank La, Erin McNamara, Frank‐Peter Theil, Jay Tibbitts, Lori S. Friedman, Cornelis E. C. A. Hop, Stephen E. Gould

    出版 2012
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  7. 7
    The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates

    The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates 由 Hans K. Erickson, Gail D. Lewis Phillips, Douglas D. Leipold, Carmela A. Provenzano, Elaine Mai, Holly A. Johnson, Bert Gunter, Charlene A. Audette, Manish Gupta, Jan Pinkas, Jay Tibbitts

    出版 2012
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  8. 8
    Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

    Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer 由 Jagath R. Junutula, Kelly M. Flagella, Richard Graham, Kathryn L. Parsons, Edward Ha, Helga Raab, Sunil Bhakta, Trung Van Nguyen, Debra L. Dugger, Guangmin Li, Elaine Mai, Gail D. Lewis Phillips, Hajime Hiraragi, Reina N. Fuji, Jay Tibbitts, Richard Vandlen, Susan D. Spencer, Richard H. Scheller, Paul Polakis, Mark X. Sliwkowski

    出版 2010
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  9. 9
    Multivalent Fcγ-receptor engagement by a hexameric Fc-fusion protein triggers Fcγ-receptor internalisation and modulation of Fcγ-receptor functions

    Multivalent Fcγ-receptor engagement by a hexameric Fc-fusion protein triggers Fcγ-receptor internalisation and modulation of Fcγ-receptor functions 由 Omar Qureshi, Tania F. Rowley, Fabian Junker, Shirley J. Peters, Siobhan Crilly, Joanne Compson, Alison Eddleston, Hanna Björkelund, Kevin Greenslade, Michael Parkinson, Nicola L. Davies, Patrick R. Griffin, Thomas L. Pither, Katharine Cain, Louis Christodoulou, Ludovicus Staelens, Emily Ward, Jay Tibbitts, Andrea Kießling, Bryan Smith, Frank R. Brennan, Magnus Malmqvist, Farnaz Fallah‐Arani, David P. Humphreys

    出版 2017
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  10. 10
    Effects of Anti-VEGF on Pharmacokinetics, Biodistribution, and Tumor Penetration of Trastuzumab in a Preclinical Breast Cancer Model

    Effects of Anti-VEGF on Pharmacokinetics, Biodistribution, and Tumor Penetration of Trastuzumab in a Preclinical Breast Cancer Model 由 Cinthia V. Pastuskovas, Eduardo E. Mundo, Simon P. Williams, Tapan K. Nayak, Jason Ho, Sheila Ulufatu, Suzanna Clark, Sarajane Ross, Fang-You Chen, Kathryn Parsons-Reponte, Gary A. Cain, Marjie Van Hoy, Nicholas Majidy, Sheila Bheddah, Josefa Chuh, Katherine R. Kozak, Nicholas Lewin‐Koh, Peter C. Nauka, Daniela Bumbaca, Mark X. Sliwkowski, Jay Tibbitts, Frank‐Peter Theil, Paul J. Fielder, Leslie A. Khawli, C. Andrew Boswell

    出版 2012
    获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: